期刊文献+

A follow-up study on newer anti-epileptic drugs as add-on and monotherapy for partial epilepsy in China 被引量:9

A follow-up study on newer anti-epileptic drugs as add-on and monotherapy for partial epilepsy in China
原文传递
导出
摘要 Background Recently,new anti-epileptic drugs (AEDs) have been more frequently selected to treat epilepsy.In the present study,we evaluated the dynamic changes of efficacy and safety of three newer AEDs for treating partial epilepsy in China.Methods Patients were collected sequentially and were divided into three groups which accepted oxcarbazepine (OXC),lamotrigine (LTG) or topiramate (TPM) therapy.Each group included monotherapy and add-on therapy subgroups.We followed all patients for one year and recorded the indexes of efficacy and safety in detail.Results A total of 909 patients finished the follow-up observation.No significant difference was found in proportion of patients with 〉 or =50% reduction,〉 or =75% reduction and 100% seizure reduction in the LTG and OXC groups between the first and the second six months.In the TPM group there was a statistical difference between the first and the second six months in proportion of patients with 〉 or =50% reduction (P=-0.002),〉 or =75% reduction (P 〈0.0001) and 100% seizure reduction (P=0.009) in the monotherapy subgroup,and about 〉 or =75% reduction and 100% seizure reduction in the add-on therapy subgroup (P 〈0.0001).The efficacy between the add-on and monotherapy subgroups showed a statistical difference.The safety of the three newer AEDs was good.Conclusions The three newer AEDs all showed good efficacy and tolerability for partial epilepsy.And the efficacy can be maintained for at least one year. Background Recently,new anti-epileptic drugs (AEDs) have been more frequently selected to treat epilepsy.In the present study,we evaluated the dynamic changes of efficacy and safety of three newer AEDs for treating partial epilepsy in China.Methods Patients were collected sequentially and were divided into three groups which accepted oxcarbazepine (OXC),lamotrigine (LTG) or topiramate (TPM) therapy.Each group included monotherapy and add-on therapy subgroups.We followed all patients for one year and recorded the indexes of efficacy and safety in detail.Results A total of 909 patients finished the follow-up observation.No significant difference was found in proportion of patients with 〉 or =50% reduction,〉 or =75% reduction and 100% seizure reduction in the LTG and OXC groups between the first and the second six months.In the TPM group there was a statistical difference between the first and the second six months in proportion of patients with 〉 or =50% reduction (P=-0.002),〉 or =75% reduction (P 〈0.0001) and 100% seizure reduction (P=0.009) in the monotherapy subgroup,and about 〉 or =75% reduction and 100% seizure reduction in the add-on therapy subgroup (P 〈0.0001).The efficacy between the add-on and monotherapy subgroups showed a statistical difference.The safety of the three newer AEDs was good.Conclusions The three newer AEDs all showed good efficacy and tolerability for partial epilepsy.And the efficacy can be maintained for at least one year.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第4期646-651,共6页 中华医学杂志(英文版)
关键词 new anti-epileptic drug partial epilepsy EFFICACY SAFETY MONOTHERAPY add-on therapy new anti-epileptic drug partial epilepsy efficacy safety monotherapy add-on therapy
  • 相关文献

参考文献27

  • 1Ding D,Hong Z,Wang WZ,Wu JZ,de Boer HM,Prilipko L,et al.Assessing the disease burden due to epilepsy by disability adjusted life year in rural China.Epilepsia 2006;47:2032-2037. 被引量:1
  • 2Rau J,May TW,Pf(a)fflin M,Heubrock D,Petermann F.Education of children with epilepsy and their parents by the modular education program epilepsy for families (FAMOSES)-results of an evaluation study.Rehabilitation (Stuttg) 2006; 45:27-39. 被引量:1
  • 3French JA,Kanner AM,Bautista J,Abou-Khalil B,Browne T, Harden CL, et al.Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society.Efficacy and tolerability of the new antiepileptic drugs Ⅰ:treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.Neurology 2004; 62:1252-1260. 被引量:1
  • 4French JA,Kanner AM,Bautista J,Abou-Khalil B,Browne T, Harden CL, et al.Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society.Efficacy and tolerability of the new antiepileptic drugs Ⅱ、:treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.Neurology 2004; 62:1261-1273. 被引量:1
  • 5Wilby J,Kainth A,Hawkins N,Epstein D,McIntosh H,McDaid C,et al.Clinical effectiveness,tolerability and cost-effectiveness of newer drugs for epilepsy in adults:a systematic review and economic evaluation.Health Technol Assess 2005; 9:1-157,iii-iv. 被引量:1
  • 6Glauser T,Ben-Menachem E,Bourgeois B,Cnaan A,Chadwick D,Guerreiro C,et al.ILAE treatment guidelines:evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.Epilepsia 2006; 47:1094-1120. 被引量:1
  • 7National Institute for Clinical Excellence.Newer drugs for epilepsy.London:NICE London; 2004.(Accessed 4 May 2004 at http://www.nice.org.uk/TA076guidance). 被引量:1
  • 8Vazquez B.Monotherapy in epilepsy:role of the newer antiepileptic drugs.Arch Neurol 2004; 61:1361-1365. 被引量:1
  • 9White HS,Smith MD,Wilcox KS.Mechanisms of action of antiepileptic drugs.Int Rev Neurobiol 2007; 81:85-110. 被引量:1
  • 10G-rosso S,Franzoni E,Iannetti P,Incorpora G,Cardinali C,Toldo I,et al.Efficacy and safety of topiramate in refractory epilepsy of childhood:long-term follow-up study.J Child Neurol 2005; 20:893-897. 被引量:1

同被引文献52

引证文献9

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部